LEXICON PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Share-based Payment Arrangement, Expense of $3.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $3.30M, a 3.13% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $3.10M, a 3.33% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $2.80M, a 86.67% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $3.40M, a 21.43% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2025 was $12.50M, a 7.41% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2024 was $13.50M, a 5.59% decline from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2023 was $14.30M, a 24.35% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2022 was $11.50M, a 8.49% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.30M 10-Q · filed 2026-08-06 | $6.40M 10-Q · filed 2026-08-06 | $9.20M derived: sum of 3 quarters · filed 2026-08-06 | $12.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.10M 10-Q · filed 2026-05-07 | $5.90M derived: sum of 2 quarters · filed 2026-05-07 | $9.30M derived: sum of 3 quarters · filed 2026-05-07 | $12.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.20M derived: sum of 2 quarters · filed 2026-03-05 | $9.40M derived: sum of 3 quarters · filed 2026-08-06 | $12.50M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.40M 10-Q · filed 2025-11-06 | $6.60M derived: sum of 2 quarters · filed 2026-08-06 | $9.70M 10-Q · filed 2025-11-06 | $11.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.20M 10-Q · filed 2026-08-06 | $6.20M 10-Q · filed 2026-08-06 | $7.70M derived: sum of 3 quarters · filed 2026-08-06 | $10.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-07 | $4.50M derived: sum of 2 quarters · filed 2026-05-07 | $7.30M derived: sum of 3 quarters · filed 2026-05-07 | $12.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.30M derived: sum of 2 quarters · filed 2026-03-05 | $9.20M derived: sum of 3 quarters · filed 2026-03-05 | $13.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.80M 10-Q · filed 2025-11-06 | $7.70M derived: sum of 2 quarters · filed 2025-11-06 | $12.00M 10-Q · filed 2025-11-06 | $15.20M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $4.90M 10-Q · filed 2025-08-06 | $9.20M 10-Q · filed 2025-08-06 | $12.40M derived: sum of 3 quarters · filed 2026-03-05 | $16.30M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $4.30M 10-Q · filed 2025-05-14 | $7.50M derived: sum of 2 quarters · filed 2026-03-05 | $11.40M derived: sum of 3 quarters · filed 2026-03-05 | $15.20M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $7.10M derived: sum of 2 quarters · filed 2026-03-05 | $10.90M derived: sum of 3 quarters · filed 2026-03-05 | $14.30M 10-K · filed 2026-03-05 |
| 2023-09-30 | $3.90M 10-Q · filed 2024-11-13 | $7.70M derived: sum of 2 quarters · filed 2024-11-13 | $11.10M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $3.80M 10-Q · filed 2024-08-02 | $7.20M 10-Q · filed 2024-08-02 | ||
| 2023-03-31 | $3.40M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $11.50M 10-K · filed 2025-03-07 | |||
| 2021-12-31 | $10.60M 10-K · filed 2024-03-25 | |||
| 2016-09-30 | $1.90M 10-Q · filed 2016-11-07 | $3.90M derived: sum of 2 quarters · filed 2016-11-07 | $5.70M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $2.00M 10-Q · filed 2016-08-04 | $3.80M 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | $1.80M 10-Q · filed 2016-05-05 | |||
| 2015-09-30 | $1.70M 10-Q · filed 2016-11-07 | $3.50M derived: sum of 2 quarters · filed 2016-11-07 | $5.40M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $1.80M 10-Q · filed 2016-08-04 | $3.70M 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $2.00M 10-Q · filed 2016-05-05 | |||
| 2014-09-30 | $1.50M 10-Q · filed 2015-11-09 | $3.30M derived: sum of 2 quarters · filed 2015-11-09 | $5.60M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $1.80M 10-Q · filed 2015-08-07 | $4.10M 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $2.30M 10-Q · filed 2015-05-05 | |||
| 2013-09-30 | $1.80M 10-Q · filed 2014-11-06 | $3.70M derived: sum of 2 quarters · filed 2014-11-06 | $5.70M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $1.90M 10-Q · filed 2014-08-07 | $4.00M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $2.10M 10-Q · filed 2014-05-08 | |||
| 2012-09-30 | $1.60M 10-Q · filed 2013-11-12 | $3.20M derived: sum of 2 quarters · filed 2013-11-12 | $4.90M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $1.60M 10-Q · filed 2013-08-01 | $3.30M 10-Q · filed 2013-08-01 | ||
| 2012-03-31 | $1.70M 10-Q · filed 2013-05-10 | |||
| 2011-09-30 | $1.40M 10-Q · filed 2012-11-07 | $4.40M 10-Q · filed 2012-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |